Physician profile
Maya Thomas
NPI 1730138629
$3,484.78
in general payments reported to CMS, 2019-2025
30 companies · $39.52 in 2025
The $39.52 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $450 · 2021: $604 · 2022: $941 · 2023: $674 · 2024: $18.78 · 2025: $39.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $760.65 | 2020-2023 | Wakix |
| Jazz Pharmaceuticals INC. | $649.21 | 2019-2025 | Xywav |
| Teva Pharmaceuticals USA, INC. | $227.55 | 2019-2023 | Austedo |
| Ucb, INC. | $211.03 | 2019-2021 | |
| Abbvie INC. | $186.51 | 2021-2025 | Qulipta, Ubrelvy |
| Vanda Pharmaceuticals INC. | $159.66 | 2022-2023 | Hetlioz |
| Philips North America LLC | $148.14 | 2019-2022 | |
| Livanova USA, INC. | $148.14 | 2019-2021 | |
| Dexcom, INC. | $130.04 | 2022-2023 | Dexcom G7 Gss (161) |
| Supernus Pharmaceuticals, INC. | $125.13 | 2019 | |
| Axsome Therapeutics, INC. | $109.06 | 2022-2024 | Sunosi, Auvelity |
| Boston Scientific Corporation | $97.00 | 2021 | |
| Neurelis, INC. | $85.54 | 2020-2023 | Valtoco |
| Lundbeck LLC | $51.33 | 2022-2023 | Vyepti |
| Idorsia Pharmaceuticals US INC | $48.48 | 2022-2023 | Quviviq |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $42.05 | 2019 | |
| Amgen INC. | $38.63 | 2019-2021 | |
| Resmed Corp | $35.07 | 2019-2020 | |
| Biogen, INC. | $32.56 | 2020-2021 | |
| Pfizer INC. | $29.41 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $21.08 | 2021 | |
| Eisai INC. | $20.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.35 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.35 | 2023 | Trulance, Xifaxan |
| Lilly USA, LLC | $18.57 | 2023 | Emgality, Reyvow |
| Genzyme Corporation | $18.50 | 2022 | |
| Alfasigma USA, INC. | $16.78 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.90 | 2023 | Gammagard |
| Merck Sharp & Dohme LLC | $13.78 | 2019 | |
| Itamar Medical INC | $6.76 | 2023 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.